Tue. 21 May 2024, 7:50am ET
Benzinga
Earnings, Earnings Beats, Earnings Misses, News
LAVA Therapeutics (NASDAQ:LVTX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.12) by 83.33 percent. This is a 96.23 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $6.99 million which missed the analyst consensus estimate of $7.00 million by 0.11 percent. This is a 471.24 percent increase over sales of $1.22 million the same period last year.